Is Wegovy the Same as Semaglutide? Brand vs Generic Disambiguation

This disambiguation explainer is part of Weight Loss Rankings’ living editorial database — 300+ research articles and 190+ clinically-reviewed GLP-1 telehealth providers, sourced only from FDA prescribing information on DailyMed and peer-reviewed PubMed literature.

Wegovy and semaglutide are not two different drugs. Wegovy is semaglutide — specifically the brand name for one FDA-approved formulation and dose of the semaglutide molecule. “Semaglutide” is the generic active-ingredient name; “Wegovy” is one of three branded products that contain it. This short article disambiguates the brand-vs-generic relationship, walks through the three FDA-approved semaglutide products, and clarifies why compounded semaglutide is not a generic Wegovy.

Wegovy IS semaglutide — the brand vs generic answer

In US drug regulation, every prescription medication has two names. The generic name (also called the United States Adopted Name, USAN, or the international nonproprietary name, INN) identifies the active molecule. The brand name identifies a specific FDA-approved product that contains that molecule. The brand name is the manufacturer’s trademark; the generic name is the molecule itself.

Wegovy is the brand name. Semaglutide is the generic name — the molecule. They are not two different drugs, any more than “Tylenol” and “acetaminophen” are two different drugs. Tylenol contains acetaminophen; Wegovy contains semaglutide. Same relationship.

Semaglutide is a 31-amino-acid synthetic analogue of native human GLP-1, designed by Novo Nordisk and first published in 2015.^[1] The molecule is a 4,113-dalton peptide with two key modifications: an aminoisobutyric acid (Aib) at position 8 that protects the peptide from dipeptidyl peptidase-4 (DPP-4) degradation, and a C18 fatty-diacid side chain attached via a γGlu-2xOEG linker that binds the peptide to circulating albumin. The albumin binding is what gives semaglutide its ~165-hour elimination half-life and once-weekly dosing for the injectable formulations.

The three FDA-approved semaglutide products

Semaglutide as a molecule is sold under three FDA-approved brand names, all manufactured by Novo Nordisk. The molecule is identical across all three; what differs is the formulation, the FDA-approved indication, and the dose.

All three brand names refer to the same active molecule. A patient asking “is Wegovy the same as semaglutide?” is typically also asking, implicitly, “is Wegovy the same as Ozempic?” and “is Wegovy the same as Rybelsus?” The answer to all three is: same molecule, different FDA-approved products. For a deep comparison of Wegovy vs Ozempic specifically — including dose ladders, trial data, and insurance coverage — see the Wegovy vs Ozempic evidence review.

The pivotal trials that supported the FDA approvals are also three separate programs, even though the molecule is one:

• STEP-1 (Wilding et al., NEJM 2021)^[2] tested semaglutide 2.4 mg once weekly in 1,961 adults with obesity but without diabetes and reported mean −14.9% body weight at 68 weeks. STEP-1 supported the Wegovy approval.
• PIONEER 1 (Aroda et al., Diabetes Care 2019)^[3] was the pivotal monotherapy trial for oral semaglutide in T2D, supporting the Rybelsus approval at doses of 3, 7, and 14 mg daily. PIONEER-6 (Husain et al., NEJM 2019)^[4] was the cardiovascular safety trial for the same oral formulation.
• The SUSTAIN program (SUSTAIN-1 through SUSTAIN-10) supported the Ozempic approval in T2D and the SUSTAIN-6 cardiovascular outcomes trial established the CV indication.

Why there is no FDA-approved generic Wegovy yet

As of 2026, the FDA has not approved any generic version of semaglutide injection. There is no generic Wegovy and no generic Ozempic. Why:

• Patent protection. Novo Nordisk holds a stack of patents covering the semaglutide molecule itself, the formulation (the buffered solution), and the prefilled-pen delivery device. Headline patent protection extends through approximately 2031-2033 depending on which specific claim is read, with manufacturing process patents stretching further. Until a key patent expires or is invalidated, no generic manufacturer can legally market semaglutide in the US.
• Biologic-vs-small-molecule complexity. Semaglutide is a peptide drug — a 31-amino-acid synthetic protein. Peptide drugs sit in a more complex regulatory category than small-molecule tablets: generic equivalents typically require not just chemistry bioequivalence but also matched immunogenicity profiles. The FDA generic-drug pathway (Abbreviated New Drug Application, ANDA) for peptides exists but adds analytical and clinical hurdles beyond what a small-molecule generic faces.
• Device patents. Even if the molecule patent expired, a generic competitor would also need to clear the single-use prefilled-pen device patents that Novo Nordisk holds. A generic manufacturer can choose to either license those device patents or design around them with a different injection system.

When the molecule and device patents expire, the FDA pathway for an approved generic semaglutide injection will open. Industry analysts currently expect the earliest US generic approvals in the 2031-2033 window, with international markets (where some patents expire earlier or are weaker) seeing generic semaglutide before then.

What about compounded semaglutide?

Compounded semaglutide is the most common source of confusion in this disambiguation. Compounded semaglutide is not a generic version of Wegovy. It is a different regulatory category entirely.

A generic drug is a copy of a brand-name product that has been reviewed and approved by the FDA through the ANDA pathway. The generic must demonstrate the same active ingredient, same dose, same route, same dosage form, and bioequivalence to the brand. Generic drugs carry FDA-approved labeling and are interchangeable with the brand from a regulatory standpoint.

A compounded drug is a medication custom-prepared by a 503A pharmacy (patient-specific) or a 503B outsourcing facility (larger-batch) for an individual prescription or a clinical need that the FDA-approved commercial supply cannot meet. Compounded drugs do not go through ANDA review, do not have FDA-approved labeling, are not demonstrated bioequivalent to the brand, and are not interchangeable with the brand from a regulatory standpoint. Compounded medications are legal under specific FDA compounding rules but they are a separate category from generics.

Compounded semaglutide became widely available from February 2023 onward because the FDA placed semaglutide injection on the official FDA Drug Shortages list, which under section 503A of the Federal Food, Drug, and Cosmetic Act authorizes pharmacies to compound a drug that would otherwise be commercially available. The FDA formally declared the semaglutide shortage resolved in February 2025. With the shortage resolved, the broad 503A compounding pathway closed.

Compounded semaglutide remains available in 2026 through narrower pathways — personalized prescriptions citing specific medical necessity (allergy substitutions, alternate-strength dosing not commercially available, etc.) — but it is no longer the broad cash-pay workaround it was in 2023-2024. For the current landscape and pricing, see the cheapest compounded semaglutide tracker and the compounded semaglutide bioequivalence evidence review.

Which semaglutide product is right for which patient

Because the three semaglutide products carry different FDA indications and dose ceilings, the choice of brand is dictated by the patient’s clinical situation, not by which name they recognize from advertising.

• Goal is weight loss, no type 2 diabetes: Wegovy. This is the only one of the three semaglutide brands FDA-approved for chronic weight management, and its 2.4 mg maintenance dose is what STEP-1 measured the −14.9% body-weight reduction against.^[2] Off-label Ozempic for weight loss will face routine insurance denials.
• Goal is type 2 diabetes glycemic control, prefers an injection: Ozempic. On-label for T2D at doses up to 2.0 mg weekly, broader insurance coverage than Wegovy.
• Goal is type 2 diabetes glycemic control, prefers a pill over an injection: Rybelsus. The only oral semaglutide, 7 mg or 14 mg daily, taken on an empty stomach with up to 4 oz of water. Bioavailability is lower than the injection, so the milligram dose is much higher but the systemic exposure ends up comparable. PIONEER 1 supported the Rybelsus approval.^[3]
• Goal is weight loss, prefers a pill: No FDA- approved option exists yet. Rybelsus is not FDA-approved for weight management. Off-label Rybelsus use for weight loss is uncommon and not supported by a pivotal weight-loss trial. The oral GLP-1 currently in late-stage development for weight loss is Eli Lilly’s orforglipron (brand name Foundayo) — a separate molecule, not semaglutide.

For a full reference list of every FDA-approved GLP-1 medication, including all three semaglutide brands plus tirzepatide (Zepbound, Mounjaro), liraglutide (Saxenda, Victoza), dulaglutide (Trulicity), and exenatide, see the full GLP-1 medication reference. For the broader disambiguation hub covering Wegovy, Ozempic, Zepbound, and Mounjaro brand relationships, see the Wegovy vs Ozempic vs Zepbound disambiguation FAQ hub.

Bottom line

• Wegovy IS semaglutide. Wegovy is the brand name for semaglutide 2.4 mg once-weekly subcutaneous injection, FDA-approved for chronic weight management.
• Three semaglutide brands exist. Wegovy (subcutaneous, 2.4 mg weekly, weight management), Ozempic (subcutaneous, 2.0 mg weekly, T2D), and Rybelsus (oral tablet, 14 mg daily, T2D). All three are Novo Nordisk; the molecule is identical across all three.
• There is no FDA-approved generic Wegovy as of 2026. Patent protection extends through approximately 2031-2033, and the FDA has not approved any ANDA for generic semaglutide injection.
• Compounded semaglutide is not a generic. It is a separate regulatory category. The FDA-shortage-driven broad 503A compounding pathway closed when the FDA declared the shortage resolved in February 2025.
• The right product depends on the indication. Weight loss without T2D → Wegovy. T2D injection → Ozempic. T2D pill → Rybelsus.

Frequently asked questions

Related research

• Wegovy vs Ozempic: same molecule, different FDA approvals — the head-to-head evidence review covering indication, dose ladder, trial data, side effects, and insurance coverage.
• Wegovy vs Ozempic vs Zepbound disambiguation FAQ hub — extends the disambiguation across drug classes, covering tirzepatide (Zepbound, Mounjaro) relationships as well.
• Full GLP-1 medication list reference — every FDA-approved GLP-1 with brand, manufacturer, indication, dose ladder, and DailyMed SetID links.
• Cheapest compounded semaglutide live tracker — the current post-shortage compounded-semaglutide pricing and regulatory landscape.
• Compounded semaglutide bioequivalence evidence review — why compounded semaglutide is not regulatorily equivalent to brand Wegovy.
• Wegovy drug profile — full label, dose ladder, side-effect rates, and provider availability.
• Semaglutide drug profile — the active ingredient overview spanning all three brand products.

Important disclaimer. This article is educational information only — not medical advice and not a substitute for consultation with a licensed prescriber. Wegovy, Ozempic, and Rybelsus are prescription medications with boxed warnings and contraindications; every clinical decision involving any of them must be made with a licensed prescriber who has reviewed the full FDA prescribing information and the individual patient’s history. Every regulatory claim in this article is anchored to a primary source (DailyMed or PubMed). Weight Loss Rankings does not prescribe, dispense, or endorse any specific medication or pharmacy.